title: Factors influencing time to sputum conversion among patients with smear-positive pulmonary tuberculosis.
abstract: For hospitalized patients with smear-positive pulmonary or laryngeal tuberculosis, the Centers for Disease Control and Prevention recommends that three consecutive sputum samples be negative for acid-fast bacilli (AFB) before respiratory isolation is discontinued. Limited data are available to predict the length of time to obtain three negative sputum smears and cultures and to determine factors associated with a prolonged interval before sputum smear and culture conversion, especially among patients infected with human immunodeficiency virus (HIV). For 100 consecutive patients with smear-positive pulmonary tuberculosis, the mean and median numbers of days from the initiation of appropriate therapy to the first of three consecutive negative smears were calculated, and associated risk factors were determined. The mean number of days before the first of three consecutive negative sputum smears was 33 days; the median was 23 days. On stepwise multiple regression analysis, cavitary disease, numerous AFB on the initial smear, and no prior history of tuberculosis were the factors independently associated with an increased number of days for both smear and culture conversion. HIV does not prolong the period of infectiousness.
authors.affiliation: Bronx Lebanon Hospital Center and the Department of Medicine, Albert Einstein College of Medicine, New York 10457, USA.
authors.forename: E E
authors.initials: EE
authors.lastname: Telzak
authors.forename: B A
authors.initials: BA
authors.lastname: Fazal
authors.forename: C L
authors.initials: CL
authors.lastname: Pollard
authors.forename: G S
authors.initials: GS
authors.lastname: Turett
authors.forename: J E
authors.initials: JE
authors.lastname: Justman
authors.forename: S
authors.initials: S
authors.lastname: Blum
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000150:complications / Q000382:microbiology / Q000635:transmission; D000995:Antitubercular Agents / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D009169:Mycobacterium tuberculosis / Q000302:isolation & purification*; D010356:Patient Isolation; D012044:Regression Analysis; D013183:Sputum / Q000382:microbiology*; D013997:Time Factors; D014397:Tuberculosis, Pulmonary / Q000150:complications / Q000382:microbiology* / Q000635:transmission
chemical_list: D000995:Antitubercular Agents